

Table S1 Prevalence of HT in patients with PTC by age at diagnosis

Characteristic	Age at diagnosis, years						
	Overall	<20	20–29	30–39	40–49	50–59	≥60
Overall							
Total	15,305 (100)	155 (1.0)	1982 (13.0)	4,572 (29.9)	4,249 (27.8)	3,388 (22.1)	959 (6.3)
HT	3,505 (22.9)	35 (22.6)	518 (26.1)	1,132 (24.8)	878 (20.7)	761 (22.5)	181 (18.9)
None-HT	11,798 (77.1)	120 (77.4)	1,464 (73.9)	3,440 (75.2)	3,371 (79.3)	2,627 (77.5)	778 (81.1)
Male							
Total	3,840 (100)	41 (1.1)	454 (11.8)	1,188 (30.9)	1,101 (28.7)	797 (20.8)	259 (6.7)
HT	463 (12.1)	7 (17.1)	66 (14.5)	161 (13.6)	116 (10.5)	83 (10.4)	30 (11.6)
None-HT	3,377 (87.9)	34 (82.9)	388 (85.5)	1,027 (86.4)	985 (89.5)	714 (89.6)	229 (88.4)
Female							
Total	11,465 (100)	114 (1.0)	1,528 (13.3)	3,384 (29.5)	3,148 (27.5)	2,591 (22.6)	700 (6.1)
HT	3,042 (26.5)	28 (24.6)	452 (29.6)	971 (28.7)	762 (24.2)	678 (26.2)	151 (21.6)
None-HT	8,423 (73.5)	86 (75.4)	1,076 (70.4)	2,413 (71.3)	2,386 (75.8)	1,913 (73.8)	549 (78.4)

Data are presented as n (%).

Table S2 Prevalence of HT in patients with PTC by primary tumor size

Characteristic	Primary tumor size, mm				
	Overall	≤10	11–20	21–40	>40
Overall					
Total	15,305 (100)	8,912 (58.2)	4,335 (28.3)	1,734 (11.3)	324 (2.1)
HT	3,505 (22.9)	2,152 (24.1)	1,003 (23.1)	323 (18.6)	27 (8.3)
None-HT	11,798 (77.1)	6,760 (75.9)	3,332 (76.9)	1,411 (81.4)	297 (91.7)
Male					
Total	3,840 (100)	2,109 (54.9)	1,129 (29.4)	476 (12.4)	126 (3.3)
HT	463 (12.1)	266 (12.6)	143 (12.7)	48 (10.1)	6 (4.8)
None-HT	3,377 (87.9)	1,843 (87.4)	986 (87.3)	428 (89.9)	120 (95.2)
Female					
Total	11,465 (100)	6,803 (59.3)	3,206 (28.0)	1,258 (11.0)	198 (1.7)
HT	3,042 (26.5)	1,886 (27.7)	860 (26.8)	275 (21.9)	21 (10.6)
None-HT	8,423 (73.5)	4,917 (72.3)	2,346 (73.2)	983 (78.1)	177 (89.4)

Data are presented as n (%).